OncoMatch/Clinical Trials/NCT07398963
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Is NCT07398963 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD19-CAR novel oncolytic vaccinia virus for refractory/relapsed b-cell lymphoma.
Treatment: CD19-CAR novel oncolytic vaccinia virus — To study the safety and effectiveness of oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T/M Therapy for Refractory/Relapsed B-Cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive (immunohistochemistry or flow cytometry)
CD19 positive (immunohistochemistry or flow cytometry)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any systemic therapy
complete remission after 2 lines of therapy; Disease progression during any course of treatment, or disease stabilization time equal to and less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation
Must have received: BTK inhibitor — MCL
MCL: Complete remission after 2 lines of treatment (including BTK inhibitors); Disease progression during any course of treatment, or disease stabilization time equal to and less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation
Cannot have received: gene therapy
Receiving gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment
Cannot have received: oncolytic virus therapy
Receiving gene therapy or any type of oncolytic virus therapy within 3 months before the study treatment
Lab requirements
Blood counts
absolute peripheral blood neutrophil ≥ 1000/mm3, platelet ≥ 50,000/mm3
Kidney function
creatinine <1.5mg/dl
Liver function
alt (alanine aminotransferase)/ast (aspartate aminotransferase) less than 2.5 times the upper limit of normal; total bilirubin < 1.5 mg/dl
Cardiac function
cardiac ejection fraction (ef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify